Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

Basilea Pharmaceutica Ltd announced that it has entered into an exclusive evaluation license and option agreement for tonabacase, with iNtRON Biotechnology, Inc., a company based in the Republic of Korea.